FDA Approves Anifrolumab (Saphnelo) as New Lupus Treatment FDA Approves Anifrolumab (Saphnelo) as New Lupus Treatment

Anifrolumab, a monoclonal antibody against type 1 interferon receptor, improved overall disease activity in patients with SLE on standard therapy, according to data from three trials.FDA Approvals
Source: Medscape Dermatology Headlines - Category: Dermatology Tags: Rheumatology News Alert Source Type: news